MX2022013401A - Compuestos de azalactama como inhibidores de hpk1. - Google Patents

Compuestos de azalactama como inhibidores de hpk1.

Info

Publication number
MX2022013401A
MX2022013401A MX2022013401A MX2022013401A MX2022013401A MX 2022013401 A MX2022013401 A MX 2022013401A MX 2022013401 A MX2022013401 A MX 2022013401A MX 2022013401 A MX2022013401 A MX 2022013401A MX 2022013401 A MX2022013401 A MX 2022013401A
Authority
MX
Mexico
Prior art keywords
sup
compounds
azalactam
hpk1 inhibitors
salts
Prior art date
Application number
MX2022013401A
Other languages
English (en)
Inventor
Sajiv Krishnan Nair
Sujin Cho-Schultz
Robert Steven Kania
Jamison Bryce Tuttle
Michele Ann Mctigue
Mehran Jalaie
Rebecca Anne Gallego
Dahui Zhou
Ru Zhou
Mingying He
Anne- Marie Dechert SCHMITT
Joyann Barber
Del Bel Matthew L
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2022013401A publication Critical patent/MX2022013401A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula general I (ver Fórmula) I y sales farmacéuticamente aceptables de los mismos, en los que R1, R2, R3a, R3b y R4 son como se definen en el presente documento, a composiciones farmacéuticas que comprenden dichos compuestos y sales, y a métodos de uso de dichos compuestos, sales y composiciones para el tratamiento del crecimiento celular anormal, incluido el cáncer.
MX2022013401A 2020-05-01 2021-04-28 Compuestos de azalactama como inhibidores de hpk1. MX2022013401A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063018689P 2020-05-01 2020-05-01
PCT/IB2021/053522 WO2021220185A1 (en) 2020-05-01 2021-04-28 Azalactam compounds as hpk1 inhibitors

Publications (1)

Publication Number Publication Date
MX2022013401A true MX2022013401A (es) 2022-11-14

Family

ID=75769663

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013401A MX2022013401A (es) 2020-05-01 2021-04-28 Compuestos de azalactama como inhibidores de hpk1.

Country Status (18)

Country Link
US (1) US11684616B2 (es)
EP (1) EP4143186A1 (es)
JP (1) JP7303948B2 (es)
KR (1) KR20230003128A (es)
CN (1) CN115698004A (es)
AR (1) AR121985A1 (es)
AU (1) AU2021265578B2 (es)
CA (1) CA3181415A1 (es)
CL (1) CL2022003007A1 (es)
CO (1) CO2022015448A2 (es)
CR (1) CR20220548A (es)
EC (1) ECSP22084264A (es)
IL (1) IL297838A (es)
MX (1) MX2022013401A (es)
PE (1) PE20230323A1 (es)
TW (1) TWI806043B (es)
UY (1) UY39193A (es)
WO (1) WO2021220185A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102650496B1 (ko) 2018-10-31 2024-03-26 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제제로서의 치환된 6-아자벤즈이미다졸 화합물
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2023057883A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Crystalline form of azalactam compound
WO2023057882A1 (en) * 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US10800773B2 (en) 2016-09-12 2020-10-13 Integral Health, Inc. Monocyclic compounds useful as GPR120 modulators
US10787435B2 (en) 2017-01-22 2020-09-29 Fuijan Cosunter Pharmaceutical Co. Ltd. ASK1 inhibitor and preparation method and use thereof
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
KR20190126322A (ko) 2017-03-03 2019-11-11 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 아미드 유도체 억제제 및 그의 제조 방법 및 적용
CN110402248B (zh) * 2017-03-15 2023-01-06 豪夫迈·罗氏有限公司 作为hpk1抑制剂的氮杂吲哚类
JOP20190221A1 (ar) 2017-04-05 2019-09-23 Seal Rock Therapeutics Inc مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها
CN109265443B (zh) * 2017-07-18 2022-11-29 南京圣和药业股份有限公司 作为ask抑制剂的杂环化合物及其应用
WO2019148005A1 (en) 2018-01-26 2019-08-01 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof
US11142525B2 (en) * 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
WO2021050964A1 (en) 2019-09-13 2021-03-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors

Also Published As

Publication number Publication date
CO2022015448A2 (es) 2022-11-18
IL297838A (en) 2023-01-01
CA3181415A1 (en) 2021-11-04
AR121985A1 (es) 2022-07-27
US11684616B2 (en) 2023-06-27
CL2022003007A1 (es) 2023-06-16
TW202202496A (zh) 2022-01-16
PE20230323A1 (es) 2023-02-22
EP4143186A1 (en) 2023-03-08
KR20230003128A (ko) 2023-01-05
AU2021265578B2 (en) 2024-03-28
TWI806043B (zh) 2023-06-21
JP7303948B2 (ja) 2023-07-05
CR20220548A (es) 2022-12-12
AU2021265578A1 (en) 2022-11-10
WO2021220185A1 (en) 2021-11-04
ECSP22084264A (es) 2022-11-30
UY39193A (es) 2021-11-30
CN115698004A (zh) 2023-02-03
US20220401424A1 (en) 2022-12-22
JP2023515900A (ja) 2023-04-14

Similar Documents

Publication Publication Date Title
MX2022013401A (es) Compuestos de azalactama como inhibidores de hpk1.
PH12021551529A1 (en) 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
PH12019500329A1 (en) Pyridopyrimdinone cdk2/4/6 inhibitors
CR20200503A (es) Inhibidores de cinasa dependientes de ciclina
CR20210627A (es) Derivados de benzisoxazol sulfonimada
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
MX2023007192A (es) Inhibidores de prmt5.
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2022005053A (es) Inhibidores de peque?as moleculas de mutante g12c de kras.
GEP20227434B (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
TN2016000529A1 (en) Substituted dihydroisoquinolinone compounds
EP3693369A3 (en) Bromodomain inhibitors
IL229136A (en) Process for making mek inhibitors
MY169142A (en) Macrocyclic derivatives for the treatment of proliferative diseases
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
UA89123C2 (ru) Производные пиримидина для лечения абнормального роста клеток
WO2011027249A3 (en) Benzimidazole derivatives
MX2021012491A (es) Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
CR20230604A (es) Inhibidores de mutación de her2
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
TN2016000459A1 (en) Cycloalkyl-linked diheterocycle derivatives.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy